SEC Form 4 · accession 0001437749-26-028846
Eton Pharmaceuticals, Inc. · ETON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Krempa
Officer — Chief Business Officer
Period of report
Aug 24, 2026
Accepted (ET)
Aug 24, 2026 · 5:19 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001710340
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 24, 2026 | M | 25,000 | $7.31 | A | 62,025 | D | |
| Common StockF1,F2 | Aug 24, 2026 | S | 25,000 | $65.07 | D | 37,025 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock OptionF3 | $7.31 | Aug 24, 2026 | M | 25,000 | D | Feb 20, 2019 | Feb 19, 2029 | Common Stock | 25,000 | 70,000 | D |
Explanation of responses
- F1The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- F2The shares were sold in multiple trades at prices ranging from $64.88 to $65.57. The price reported above reflects the weighted average sales price.
- F3The shares subject to the option vested in 48 equal monthly installments from the date of grant (2-20-2019) until fully vested.
Remarks
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.